1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-249.
2.
Schabath MB, Cote ML. Cancer progress and priorities: lung cancer. Cancer Epidemiol Biomarkers Prev 2019; 28: 1563-1579.
3.
Chen B, Li CW. Big mechanisms in systems biology. Elsevier 2017.
4.
Tsay JCJ, Greenberg AK, Rom WN, Massion PP. Preclinical biomarkers for the early detection of lung cancer. IASLC Thor Oncol Elsevier 2018; 59-68: e4.
5.
Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007; 19: 813-824.
6.
Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027-1034.
7.
Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albac- ker LA, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 2006; 203: 883-895.
8.
Shukuya T, Carbone DP. Predictive markers for the efficacy of anti–PD-1/PD-L1 antibodies in lung cancer. J Thor Oncol 2016; 11: 976-988.
9.
Han W, Ding P, Xu M, Wang L, Rui M, Shi S, et al. Identification of eight genes encoding chemokine-like factor superfamily members 1–8 (CKLFSF1–8) by in silico cloning and experimental validation. Genomics 2003; 81: 609-617.
10.
Wu K, Li X, Gu H, Yang Q, Liu Y, Wang L. Research advances in CKLF-like MARVEL transmembrane domain-containing family in non-small cell lung cancer. Int J Biol Sci 2019; 15: 2576.
11.
Lu J, Wu QQ, Zhou YB, Zhang KH, Pang BX, Li L, et al. Cancer research advances regarding the CKLF-like MARVEL transmembrane domain containing family. Asian Pac J Cancer Prev 2016; 17: 2741-2744.
12.
Mohapatra P, Shriwas O, Mohanty S, Ghosh A, Smita S, Kaushik SR, et al. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3 axis. JCI Insight 2021; 6: e143643.
13.
Burr ML, Sparbier CE, Chan YC, Williamson JC, Woods K, Beavis PA, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature 2017; 549: 101-105.
14.
Mezzadra R, Sun C, Jae LT, Gomez-Eerland R, De Vries E, Wu W, et al. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature 2017; 549: 106-110.
15.
Jia D, Xiong L, Xue H, Li J. CMTM6 is highly expressed in lung adenocarcinoma and can be used as a biomarker of a poor diagnosis. Peer J 2023; 11: e14668.
16.
Hou X, He S, Zhang D, Yang C, Shi Y, Zhang K. Expression and clinical significance of CMTM6 in nonsmall cell lung cancer. DNA Cell Biol 2020; 39: 2265-2271.
17.
Wang H, Gao J, Zhang R, Li M, Peng Z, Wang H. Molecular and immune characteristics for lung adenocarcinoma patients with CMTM6 overexpression. Int Immunopharmacol 2020; 83: 106478.
18.
Gainor JF, Rizvi H, Aguilar EJ, Skoulidis F, Yeap BY, Naidoo J, et al. Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥ 50%. Ann Oncol 2020; 31: 404-411.
19.
Igarashi T, Teramoto K, Ishida M, Hanaoka J, Daigo Y. Scoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factors. ESMO Open 2016; 1: e000083.
20.
Koh YW, Han JH, Haam S, Jung J, Lee HW. Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients. Oncoimmunology 2019; 8: e1629261.
21.
Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, et al. The 2021 WHO classification of lung tumors: impact of advances since 2015. J Thor Oncol 2021; 17.
22.
Jia X min, Long Y ru, Yu X lu, Chen R qiu, Gong L kun, Geng Y. Construction of stable membranal CMTM6-PD-L1 full-length complex to evaluate the PD-1/PD-L1-CMTM6 interaction and develop anti-tumor anti-CMTM6 nanobody. Acta Pharmacol Sin 2022.
23.
Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013; 19: 1423-1437.
24.
Corredor G, Wang X, Zhou Y, Lu C, Fu P, Syrigos K, et al. Spatial architecture and arrangement of tumor-infiltrating lymphocytes for predicting likelihood of recurrence in early-stage non-small cell lung cancer. Clin Cancer Res 2019; 25: 1526-1534.
25.
Zugazagoitia J, Liu Y, Toki M, McGuire J, Ahmed FS, He-nick BS, et al. Quantitative assessment of CMTM6 in the tumor microenvironment and association with response to PD-1 pathway blockade in advanced-stage non-small cell lung cancer. J Thor Oncol 2019; 14: 2084-2096.
26.
Dai F, Duan Y lian, Feng Q, Song SL, Yang JL, Lv T. CMTM6: a critical prognostic indicator in non-small cell lung cancer. J Cancer 2024; 15: 2373.
27.
Gao F, Chen J, Wang J, Li P, Wu S, Wang J, et al. CMTM6, the newly identified PD-L1 regulator, correlates with PD-L1 expression in lung cancers. Biochem Biophys Rep 2019; 20: 100690.
28.
Yugawa K, Itoh S, Yoshizumi T, Iseda N, Tomiyama T, Morinaga A, et al. CMTM6 stabilizes PD-L1 expression and is a new prognostic impact factor in hepatocellular carcinoma. Hepatol Commun 2021; 5: 334-348.
29.
Pang X, Wang SS, Zhang M, Jiang J, Fan HY, Wu JS, et al. OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway. Cancer Immunol Immunother 2021; 70: 1015-1029.
30.
Gagné A, Enlow W, Pigeon MA, Orain M, Turcotte S, Bossé Y, et al. Comprehensive assessment of PD-L1 staining heterogeneity in pulmonary adenocarcinomas using tissue microarrays. Am J Surg Pathol 2018; 42: 687-694.
31.
Reiniger L, Téglási V, Pipek O, Rojkó L, Glasz T, Vágvölgyi A, et al. Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma. Acta Oncol (Madr) 2019; 58: 1087-1094.
32.
Pawe³czyk K, Piotrowska A, Ciesielska U, Jablonska K, Glatzel- Plucinska N, Grzegrzolka J, et al. Role of PD-L1 expression in non-small cell lung cancer and their prognostic significance according to clinicopathological factors and diagnostic markers. Int J Mol Sci 2019; 20: 824.
33.
Jiang L, Su X, Zhang T, Yin X, Zhang M, Fu H, et al. PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC). Oncotarget 2017; 8: 26845.
34.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69: 7-34.
